Common Bile Duct Stricture
Conditions
Keywords
metal stent, common bile duct obstruction, endoscopic retrograde cholangiopancreatography
Brief summary
If surgical treatment is not possible in patients with malignant obstruction in the common bile duct, placing metal stents using endoscopy is a standardized treatment to resolve biliary obstruction. The metal stent is located in the bile duct to cover the stenotic portion by malignant tumors. The lower end of the metal stent can be located inside the common bile duct above the major ampulla or in the duodenum through the major ampulla. These two procedures with supra- or trans-papillary stents are currently being performed in general clinical practices, depending on the preference of the endoscopists. Until now, the comparison of the clinical results of the two procedures has been scarcely studied, and there is no prospective study yet. Therefore, researchers aim to compare the clinical results of two stent procedures through prospective randomized controlled studies.
Detailed description
If surgical treatment is not possible in patients with malignant obstruction in the common bile duct, endoscopic metal stent placement to resolve biliary obstruction is a standard treatment that is commonly performed. The metal stents relieve the bile duct stenosis by malignant tumors, helping to drain the bile and improving jaundice. There is no doubt that the center of the metal stent is located in the central part of the biliary stricture, but the location of the lower end of the metal stent is not fixed. The lower end of the metal stent can be located in two main locations, either in the common bile duct above the major ampulla or in the duodenum through the major ampulla. These procedures with supra- or trans-papillary stents are performed in common and are determined by the operator's preference. According to several retrospective studies so far, trans-papillary metal stents were effective in improving the initial biliary obstruction, but there was no difference in their long-term effects. Mao et al. showed that trans-papillary metal stents increase jaundice-free survival, and Shin et al. revealed the advantages of trans-papillary metal stents because they had a high success rate of secondary endoscopic procedures. On the contrary, Okamoto et al. showed that acute cholangitis more developed after trans-papillary metal stents placement, while Joe et al. revealed the advantages of supra-papillary metal stents because they reduce acute pancreatitis after the procedures. It has not yet been determined which method is effective. So far studies are all retrospective, and some of them placed the metal stents in a percutaneous way rather than endoscopy without sphincterotomy. Besides, some studies included intra-hepatic or hilar bile duct strictures, making it difficult to interpret the results. Therefore, through a prospective randomized controlled study, the researchers want to compare the clinical results of supra- and trans-papillary metal stents placed by endoscopes in malignant common bile duct obstruction.
Interventions
PROCEDUREMetal stent placement
Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Sponsors
Seoul St. Mary's Hospital
Incheon St.Mary's Hospital
St Vincent's Hospital
Bucheon St. Mary's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Assigned groups are secreted to the participant and outcome assessors
Intervention model description
1. supra-papillary metal stent group 2. trans-papillary metal stent group
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with common bile duct obstruction due to malignancy
Exclusion criteria
* intrahepatic or perihilar bile duct obstruction (except Klatskin type I) * patients who have operability or want surgery * strictures located within 2 cm from the end of distal common bile duct * patients who are not able to undergo endoscopy due to cardiovascular or pulmonary diseases * patients whose informed consents are not received * patients in whom an endoscope can not access to the ampulla due to anatomical deformity by previous surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stent function maintenance duration | through study completion, an average of 1 year | jaundice free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| stone or sludge occurrence | through study completion, an average of 1 year | in-stent or above stent bile duct stone formation |
| in-stent stenosis or tumor overgrowth | through study completion, an average of 1 year | stenosis due to tumor growth: in-stent or over the stent |
| acute cholangitis occurrence | through study completion, an average of 1 year | after procedure acute cholangitis occurrence rate |
| stent migration rate | through study completion, an average of 1 year | spontaneous migration rate |
| overall survival | From date of randomization until the date of date of death from any cause, assessed up to 36 months | duration between stent placement and death |
Countries
South Korea
Contacts
Primary ContactJae Hyuck Chang, Ph, Dr
Outcome results
None listed